Neutropaenia complications from Ocrelizumab and Rituximab treatment

• DOI: 10.1016/j.msard.2023.105147
• Publication Date: 2023-11-21T05:52:34Z
• Authors: Venus Pang; Nabil Seery; Robb Wesselingh; Wei Yeh; Michael Zhong; Tracie Tan; Chris Dwyer; Cassie Nesbitt; Louise Rath; Deborah Perera; Francesca Bridge; Olga Skibina; Julian J. Bosco; Vilija Jokubaitis; Mark Marriott; Helmut Butzkueven; Anneke Van Der Walt; Jennifer Massey; Ian Sutton; Mastura Monif
• Keywords: Ocrelizumab; Ofatumumab; Neuromyelitis Optica

Ocrelizumab is an anti-CD20 monoclonal antibody (mAb) that has been shown in phase 3 clinical trials to reduce relapses and disease progression multiple sclerosis (MS) patients. Prior the approval of ocrelizumab, rituximab, a chimeric mAb was used treat MS. Rituximab still MS many countries outside Australia remains mainstay treatment non-MS neuroimmunological systemic inflammatory diseases. currently neuromyelitis optica spectrum disorder (NMOSD) autoimmune encephalitis, addition its widespread usage hematological malignancies approved for relapsing-remitting (RRMS). Neutropaenia rare complication both ocrelizumab rituximab treatment. This case series reports 12 patients who have experienced neutropaenia following or aims characterize parameters by these patients, including severity duration neutropaenia, length hospital admission, types subsequent infections necessary before reached count recovery. The unpredictability potential serious highlight need continued monitoring on B-cell depleting therapies calls careful patient counselling provide guidance whether continue such related neutropaenia.